Resveratrol-induced apoptotic cell death in glioma

白藜芦醇诱导神经胶质瘤细胞凋亡

基本信息

  • 批准号:
    7477902
  • 负责人:
  • 金额:
    $ 17.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-08-01 至 2009-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Glioma is a malignant brain tumor in adults, difficult to treat and resistant to conventional radiotherapy and chemotherapy. Several major signaling cascades have been implicated in the development of gliomas, which include over-expression and activation of growth factors and their receptors (i.e. EGFR), over-expression and activation of intracellular signaling proteins (i.e. PI3-K/Akt) and deregulation of cell proliferation and the cell cycle. Resveratrol (trans-3,4',5-trihydroxystilbene) is a polyphenolic compound highly enriched in grapes, peanuts, red wine and a variety of plant and food sources. Resveratrol has been reported to have anti-inflammatory and antioxidant properties and acts as a cancer chemopreventive agent, inhibiting different steps of the carcinogenesis process, such as tumor initiation, promotion and progression. However, the signaling mechanisms mediated by resveratrol are not well defined in vivo. Our published in vitro studies show that resveratrol suppresses cell proliferation and induces apoptotic cell death in human U251 glioma cells in a dose- and time-dependent manner. Activation of caspases and suppression of phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (Akt)-mediated signaling pathways are involved in this process. In the current study, we investigate the effect of resveratrol on the suppression of tumor growth and its underlying molecular mechanism in vivo using a U251 intracerebral glioma model in nude mice. We hypothesize that resveratrol suppresses the development of glioma in vivo through the down-regulation of expression and/or suppression of the activation of EGFR- and PI3-K/Akt-mediated signaling pathways. Specifically, the effect of resveratrol on the tumor growth will be determined and the regulation of EGFR/PI3-K/Akt-mediated signaling pathways by resveratrol will be examined. Natural products, such as resveratrol, usually have little or no toxic effects, are low cost and can be consumed orally. Development of potential preventive or adjunctive therapies using such products will be of great benefit for the treatment of glioma, as well as other human diseases. Glioma is a malignant brain tumor in adults, which is difficult to treat and resistant to conventional radiotherapy and chemotherapy. Resveratrol is a polyphenolic compound highly enriched in grapes, peanuts, red wine and a variety of plant and food sources. Resveratrol has anti-inflammatory and antioxidant properties and acts as a cancer chemopreventive agent. Our in vitro studies show that resveratrol suppresses cell proliferation and induces apoptotic cell death in glioma cells. Therefore, we seek to test the effect of resveratrol in vivo using a well-established animal model of glioma. By elucidating the molecular mechanisms underlying the therapeutic effects of resveratrol, this study would facilitate the development of therapeutic agents using natural products and greatly improve the treatment of brain tumors.
描述(申请人提供):胶质瘤是一种成人恶性脑瘤,难以治疗,对常规放疗和化疗耐药。神经胶质瘤的发生与多种信号转导通路有关,包括生长因子及其受体(即EGFR)的过度表达和激活,细胞内信号蛋白(即PI3-K/Akt)的过度表达和激活,以及对细胞增殖和细胞周期的调控。白藜芦醇(反式-3,4‘,5-三羟基二苯乙烯)是一种多酚化合物,在葡萄、花生、红酒和各种植物和食物来源中高度丰富。白藜芦醇已被报道具有抗炎和抗氧化特性,并作为癌症化学预防药物,抑制肿瘤发生、促进和进展等不同阶段的致癌过程。然而,白藜芦醇在体内介导的信号转导机制还不是很清楚。我们发表的体外研究表明,白藜芦醇以剂量和时间依赖的方式抑制人U251胶质瘤细胞的增殖和诱导细胞凋亡。半胱氨酸氨基转移酶的激活和磷脂酰肌醇3-激酶(PI3-K)/蛋白激酶B(Akt)介导的信号通路的抑制参与了这一过程。在本研究中,我们利用裸鼠U251脑内胶质瘤模型,研究了白藜芦醇对肿瘤生长的抑制作用及其分子机制。我们假设白藜芦醇在体内通过下调和/或抑制EGFR-和PI3-K/Akt介导的信号通路的表达和/或激活来抑制胶质瘤的发展。具体来说,将确定白藜芦醇对肿瘤生长的影响,并研究白藜芦醇对EGFR/PI3-K/Akt介导的信号通路的调节。天然产品,如白藜芦醇,通常毒性很小或没有影响,成本低,可以口服。利用这些产品开发潜在的预防性或辅助疗法将对胶质瘤和其他人类疾病的治疗大有裨益。胶质瘤是一种成人恶性脑瘤,治疗难度大,对常规放疗和化疗耐药。白藜芦醇是一种多酚化合物,高度富含葡萄、花生、红酒和各种植物和食物来源。白藜芦醇具有抗炎和抗氧化特性,是一种癌症化学预防药物。我们的体外研究表明,白藜芦醇抑制胶质瘤细胞的增殖和诱导细胞凋亡。因此,我们试图使用一个成熟的胶质瘤动物模型来测试白藜芦醇在体内的作用。通过阐明白藜芦醇治疗作用的分子机制,本研究将促进利用天然产品开发治疗药物,并极大地提高脑肿瘤的治疗效果。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells.
  • DOI:
  • 发表时间:
    2009
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Hao Jiang;Xia Shang;Hongtao Wu;S. Gautam;Shaza N Al-Holou;Christina Li;J. Kuo;Lijie Zhang;M. Chopp
  • 通讯作者:
    Hao Jiang;Xia Shang;Hongtao Wu;S. Gautam;Shaza N Al-Holou;Christina Li;J. Kuo;Lijie Zhang;M. Chopp
Combination treatment with resveratrol and sulforaphane induces apoptosis in human U251 glioma cells.
  • DOI:
    10.1007/s11064-009-0040-7
  • 发表时间:
    2010-01
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Jiang, Hao;Shang, Xia;Wu, Hongtao;Huang, Grace;Wang, Yiyang;Al-Holou, Shaza;Gautam, Subhash C.;Chopp, Michael
  • 通讯作者:
    Chopp, Michael
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HAO JIANG其他文献

HAO JIANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HAO JIANG', 18)}}的其他基金

SBIR TOPIC 417: QUANTITATIVE IMAGING SOFTWARE TOOLS FOR CANCER DIAGNOSIS AND TREATMENT PLANNING
SBIR 主题 417:用于癌症诊断和治疗计划的定量成像软件工具
  • 批准号:
    10924835
  • 财政年份:
    2023
  • 资助金额:
    $ 17.76万
  • 项目类别:
Development of Multilayer Strip Ion Chamber Device for the Measurement of Proton FLASH-Radiotherapy
用于测量质子闪光放射治疗的多层条形电离室装置的开发
  • 批准号:
    10714482
  • 财政年份:
    2022
  • 资助金额:
    $ 17.76万
  • 项目类别:
SBIR TOPIC 417 Multiple Brain Metastases Stereotactic Radiosurgery Management Platform - Detection, Planning and Follow-up
SBIR TOPIC 417 多发性脑转移瘤立体定向放射外科管理平台 - 检测、规划和随访
  • 批准号:
    10496726
  • 财政年份:
    2021
  • 资助金额:
    $ 17.76万
  • 项目类别:
SBIR TOPIC 417 Multiple Brain Metastases Stereotactic Radiosurgery Management Platform - Detection, Planning and Follow-up
SBIR TOPIC 417 多发性脑转移瘤立体定向放射外科管理平台 - 检测、规划和随访
  • 批准号:
    10579810
  • 财政年份:
    2021
  • 资助金额:
    $ 17.76万
  • 项目类别:
Resveratrol-induced apoptotic cell death in glioma
白藜芦醇诱导神经胶质瘤细胞凋亡
  • 批准号:
    7313929
  • 财政年份:
    2007
  • 资助金额:
    $ 17.76万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.76万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 17.76万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 17.76万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 17.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 17.76万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 17.76万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 17.76万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 17.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 17.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 17.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了